HomeOnvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response

Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response

San Diego, 28.04.2020

We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) :